## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

			" <u></u>
In re Applicat	ion of: SOUTHAM, Mary, et al.	)	
	Sootin tivi, Mary, et al.	) Group Art Unit:	207
Serial No:		) ) Examiner:	
Filed:		)	
For:	DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL	) ) . ) . )	
Assistant Com Washington, I	missioner for Patents D.C. 20231		
	INFORMATION DISCLOS	URE STATEMENT	
Sir:			
which they bel application, an While C.F.R. § 1.56 referred to her referenced app where appropr	ants submit herewith patents, publications are lieve an examiner may consider to be material and in respect of which there may be a duty to this Information Disclosure Statement may consider it is not intended to constitute an admission ein is either "material" or "prior art" to the elication unless specifically designated as such iate, to avoid or antedate any such reference 131 and § 1.608, or any other appropriate in	al to the patentability of the claim disclose in accordance with 37 Contain "material" information put that any patent, publication or of invention disclosed and claimed in Applicants specifically reserve by the appropriate arguments or	ns of this C.F.R. § 1.56. Irsuant to 37 ther information in the above- e the right,
submitted here returned to the	•	caminer initialed copy of the PTC	) Form 1449 be
⊠ A 0	copy of each reference therein listed accomp	anies this information Disclosure	statement.
☐ NO under :	O copies of the references therein listed according to the references therein listed according to the control of the control o		ent Office in

filing date under 35 U.S.C. § 120.

Page 2 of 3

This Information Disclosure Statement is not a representation that a search has been made or that no other information material to the patentability of this invention exists.

national stage whichever is than 90 days	tion Disclosure Statement is being filed within three months of the filing or entry of the of this application, or before the mailing of a first Office Action on the merits, later. No fee is required under 37 C.F.R. § 1.97(b). However, in the event that more from filing have elapsed and a first Office Action on the merits has been mailed, the r is hereby authorized to charge the fee required under 37 C.F.R. 1.17(p) to Deposit aber 01-1173.
or entry of the	ion Disclosure Statement is being submitted after three months from the date of filing e national stage or this application, or after the mailing of a first Office Action, later, but before the mailing date of either a final Office Action or a Notice of
Depos -OR-	missioner is hereby authorized to charge the fee required under 37 C.F.R. § 1.17(p) to sit Account 01-1173 on as specified in 37 C.F.R. § 1.97(e) follows:
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of this statement.
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Page 3 of 3

The Examiner is hereby requested to consider these references and other information and make them of record in the above-referenced application. Applicants respectfully submit that the claims of this application are patentable over the above-cited references and information. Examination and allowance of this application at an early date are requested.

Respectfully submitted,

Date:

\_

Christopher P. Rogers, Registra

Registration No. 36,334

ALZA Corporation 950 Page Mill Road PO Box 10950 Palo Alto, CA 94303-0802 (415) 496-8267

## CERTIFICATE OF MAILING

ALZA CORPORATION

Hanriotta Votav